Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study.

@article{Wei2007CombinedTO,
  title={Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study.},
  author={Yanzhang Wei and Robert P. Sticca and Jin H. Li and Lillia M. Holmes and Kelly E Burgin and Susan Jakubchak and Hilary Bouton-Verville and Jane Williamson and Karen M Meyer and Lyndon Evans and Julie E Martin and Joseph J. Stephenson and S. Trocha and Sam Smith and Thomas E. Wagner},
  journal={Oncology reports},
  year={2007},
  volume={18 3},
  pages={665-71}
}
Vaccination using dendritic/tumor cell hybrids represents a novel and promising cancer immunotherapy. We have developed a technology that can instantly purify the hybrids (dendritomas) from the fusion mixture of dendritic cells (DCs) and tumor cells. Our animal studies and a phase I study of stage IV melanoma patients demonstrated that dendritoma vaccination could be conducted without major toxicity and induced tumor cell-specific immunological and clinical responses. In this pilot study, ten… CONTINUE READING
18 Citations
22 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…